Newly released data reveals that seven out of 67 children treated with Bluebird Bio Inc's (NASDAQ:BLUE) gene therapy for a ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Stellantis (STLA) confirmed that its CEO Carlos Tavares will retire in early 2026 at the end of his contract. Read more ...

A Bluebird Bio gene therapy has helped children with a devastating neurological disorder, but seven have developed blood ...

Seven out of 67 children who were given bluebird's (BLUE) gene therapy Skysona during clinical trials ended up developing ...

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...